Abstract: The present invention generally relates to the use of extracellular vesicles derived from cardiosphere-derived cells (CDC-EVs) as an anti-shock therapeutic. For instance, the present invention relates to a method of using CDC-EVs to treat polytrauma associated with coagulopathy and hemorrhagic shock in a subject in need thereof, wherein the lactate, glucose and/or creatinine levels in the subject are decreased upon being treated with a therapeutically effective amount of CDC-EVs. The results presented herein are of great relevance to the development of EV products for use in combat casualty care, as the studies presented herein show that CDC-EVs have the potential to be an anti-shock therapeutic if administered immediately after injury involving trauma associated with hemorrhagic shock and/or coagulopathy.